Lisa Coussens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8324817/publications.pdf

Version: 2024-02-01

91828 61945 23,002 75 43 69 citations h-index g-index papers 81 81 81 33009 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nature Methods, 2022, 19, 311-315.	9.0	102
2	Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma. Npj Precision Oncology, 2022, 6, 10.	2.3	23
3	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Reports Medicine, 2022, 3, 100525.	3.3	22
4	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery, 2022, 21, 440-462.	21.5	58
5	MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 2022, 19, 262-267.	9.0	37
6	Early detection of cancer. Science, 2022, 375, eaay9040.	6.0	291
7	T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62. Molecular Cancer Research, 2022, 20, 1151-1165.	1.5	O
8	Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical Cancer Research, 2022, 28, 903-914.	3.2	14
9	Novel Therapeutics Modulate Cardiac Leukocyte Populations Following Myocardial Infarction. FASEB Journal, 2022, 36, .	0.2	O
10	Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach. Frontiers in Immunology, 2022, 13, .	2.2	6
11	A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. Nature Biotechnology, 2022, 40, 1823-1833.	9.4	17
12	Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nature Materials, 2021, 20, 548-559.	13.3	125
13	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 1069-1081.	3.2	75
14	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discovery, 2021, 11, 2014-2031.	7.7	79
15	High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. Breast Cancer Research, 2021, 23, 40.	2.2	18
16	Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Annals of Oncology, 2021, 32, 600-608.	0.6	69
17	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4574-4586.	3.2	82
18	Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. Journal of Thoracic Oncology, 2021, 16, 1211-1223.	0.5	17

#	Article	IF	Citations
19	Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial. , 2021, , .		O
20	Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. Npj Precision Oncology, 2021, 5, 92.	2.3	11
21	Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs. Cancer Cell, 2021, 39, 1300-1302.	7.7	3
22	Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 769534.	2.2	12
23	Abstract PO-095: A cancer cell-intrinsic GOT2-PPARδaxis suppresses antitumor immunity., 2021,,.		0
24	Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. Cancer Immunology Research, 2020, 8, 131-145.	1.6	21
25	Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. Cancer Discovery, 2020, 10, 1489-1499.	7.7	60
26	Zena Werb 1945–2020. Nature Cancer, 2020, 1, 753-754.	5.7	1
27	High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. Methods in Enzymology, 2020, 635, 1-20.	0.4	57
28	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 3578-3588.	3.2	76
29	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
30	Innate \hat{l} T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. Cancer Discovery, 2019, 9, 1288-1305.	7.7	19
31	Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research, 2019, 25, 5787-5798.	3.2	72
32	Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 2019, 30, 36-50.	7.2	933
33	The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nature Communications, 2019, 10, 4682.	5.8	123
34	Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 389-398.	1.1	17
35	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 5351-5363.	3.2	57
36	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , $2019, 7, 131.$		64

3

#	Article	IF	CITATIONS
37	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174.	1.8	123
38	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	1.6	70
39	Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. Head and Neck, 2019, 41, 2636-2646.	0.9	20
40	Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell, 2019, 35, 588-602.e10.	7.7	636
41	Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. Blood Advances, 2019, 3, 3080-3091.	2.5	22
42	Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nature Cell Biology, 2019, 21, 190-202.	4.6	384
43	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	15.2	3,421
44	TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell, 2018, 33, 60-74.e6.	7.7	270
45	Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	6.0	3,126
46	Targeting myeloid-inflamed tumor with anti-CSF- $1R$ antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. , 2018, 6, 118.		43
47	Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell, 2018, 34, 561-578.e6.	7.7	113
48	Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer., 2018, 6, 98.		43
49	Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances, 2018, 4, eaat7828.	4.7	203
50	Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity, 2018, 49, 178-193.e7.	6.6	502
51	Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Reports, 2017, 19, 203-217.	2.9	454
52	Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis. Journal of Visualized Experiments, 2017, , .	0.2	5
53	Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma Transition. Cancer Discovery, 2017, 7, 1098-1115.	7.7	185
54	Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis. Journal of Investigative Dermatology, 2017, 137, 359-366.	0.3	21

#	Article	IF	CITATIONS
55	Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. JCI Insight, $2016,1,.$	2.3	13
56	MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nature Communications, 2016, 7, 13597.	5.8	54
57	Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. Cancer Discovery, 2016, 6, 22-35.	7.7	69
58	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncolmmunology, 2016, 5, e1136044.	2.1	55
59	The Basis of Oncoimmunology. Cell, 2016, 164, 1233-1247.	13.5	671
60	Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discovery, 2016, 6, 270-285.	7.7	408
61	Senescence and cancer: An evolving inflammatory paradox. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 14-22.	3.3	35
62	Sustained Endothelial Expression of HoxA5 In Vivo Impairs Pathological Angiogenesis And Tumor Progression. PLoS ONE, 2015, 10, e0121720.	1.1	20
63	TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunology Research, 2015, 3, 518-525.	1.6	197
64	Macrophages and Therapeutic Resistance in Cancer. Cancer Cell, 2015, 27, 462-472.	7.7	1,130
65	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75.	3.8	101
66	Duality of the Immune Response in Cancer: Lessons Learned from Skin. Journal of Investigative Dermatology, 2014, 134, E23-E28.	0.3	23
67	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell, 2014, 26, 623-637.	7.7	751
68	Manipulating MicroRNAs to Regulate Macrophage Polarization in Gliomas. Journal of the National Cancer Institute, 2014, 106, dju230-dju230.	3.0	6
69	A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice. Gastroenterology, 2014, 146, 1784-1794.e6.	0.6	118
70	B cells and their mediators as targets for therapy in solid tumors. Experimental Cell Research, 2013, 319, 1644-1649.	1.2	63
71	Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?. Science, 2013, 339, 286-291.	6.0	943
72	CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 ⁺ T cells. Oncolmmunology, 2013, 2, e26968.	2.1	311

LISA COUSSENS

#	Article	IF	CITATIONS
73	Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2796-2801.	3.3	393
74	Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell, 2012, 21, 309-322.	7.7	3,578
75	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	7.7	1,486